{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:11:26Z","timestamp":1790665886315,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.prrv.2022.11.005","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:05:17Z","timestamp":1670249117000},"page":"23-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Cystic fibrosis related diabetes (CFRD) in the era of modulators: A scoping review"],"prefix":"10.1016","volume":"46","author":[{"given":"Bernadette","family":"Prentice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7366-193X","authenticated-orcid":false,"given":"Grace Y.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.prrv.2022.11.005_b0005","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2022.11.005_b0010","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prrv.2022.11.005_b0015","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation. Results of a two-part phase 3 clinical trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.prrv.2022.11.005_b0020","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.prrv.2022.11.005_b0025","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S2213-2600(21)00069-2","article-title":"Long-term safety of lumacaftor\u2013ivacaftor in children aged 2\u20135 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study","volume":"9","author":"Hoppe","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.prrv.2022.11.005_b0030","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S2213-2600(20)30517-8","article-title":"Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6\u201311 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study","volume":"9","author":"Chilvers","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.prrv.2022.11.005_b0035","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6\u201311 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"17","key":"10.1016\/j.prrv.2022.11.005_b0040","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.prrv.2022.11.005_b0045","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.prrv.2022.11.005_b0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2020.07.023","volume":"20","author":"Davies","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.prrv.2022.11.005_b0055","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jcf.2019.06.009","article-title":"A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis","volume":"18","author":"Walker","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.prrv.2022.11.005_b0060","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jcf.2022.02.003","article-title":"A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor\/ivacaftor in children \u2265 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant","volume":"21","author":"Sawicki","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"19","key":"10.1016\/j.prrv.2022.11.005_b0065","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.prrv.2022.11.005_b0070","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.prrv.2022.11.005_b0075","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1513\/AnnalsATS.201909-671CME","article-title":"The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis","volume":"17","author":"Sergeev","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.prrv.2022.11.005_b0080","doi-asserted-by":"crossref","unstructured":"Gelfond, D. et al. Impact of CFTR Modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation. Clin Transl Gastroenterol 8, e81 (2017).","DOI":"10.1038\/ctg.2017.10"},{"key":"10.1016\/j.prrv.2022.11.005_b0085","doi-asserted-by":"crossref","unstructured":"Ferrera, L., Baroni, D., Moran, O. Lumacaftor-rescued F508del-CFTR has a modified bicarbonate permeability. J Cyst Fibros 18, 602\u2013605 (2019).","DOI":"10.1016\/j.jcf.2019.01.012"},{"key":"10.1016\/j.prrv.2022.11.005_b0090","unstructured":"Cystic fibrosis related diabetes in Europe: Prevalence, risk factors and outcome; Olesen et al - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/31680042\/."},{"issue":"159","key":"10.1016\/j.prrv.2022.11.005_b0095","doi-asserted-by":"crossref","first-page":"200293","DOI":"10.1183\/16000617.0293-2020","article-title":"Cystic fibrosis-related diabetes and lung disease: an update","volume":"30","author":"Prentice","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"9","key":"10.1016\/j.prrv.2022.11.005_b0100","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.prrv.2022.11.005_b0105","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.prrv.2022.11.005_b0110","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.2337\/dc10-1279","article-title":"Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.prrv.2022.11.005_b0115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/eje.1.01836","article-title":"Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis","volume":"152","author":"Tof\u00e9","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.prrv.2022.11.005_b0120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1399-5448.2009.00632.x","article-title":"Oral glucose tolerance testing in children with cystic fibrosis","volume":"11","author":"Ode","year":"2010","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.prrv.2022.11.005_b0125","doi-asserted-by":"crossref","unstructured":"Kasim, N., Khare, S., Sandouk, Z., Chan, C. Impaired glucose tolerance and indeterminate glycemia in cystic fibrosis. J Clin Transl Endocrinol 26, 100275 (2021).","DOI":"10.1016\/j.jcte.2021.100275"},{"issue":"6","key":"10.1016\/j.prrv.2022.11.005_b0130","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcf.2019.03.010","article-title":"Early glucose abnormalities are associated with pulmonary inflammation in young children with cystic fibrosis","volume":"18","author":"Prentice","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.prrv.2022.11.005_b0135","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jcf.2018.03.008","article-title":"Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline","volume":"17","author":"Chan","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.prrv.2022.11.005_b0140","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S2213-8587(17)30400-X","article-title":"Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial","volume":"6","author":"Ballmann","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.prrv.2022.11.005_b0145","doi-asserted-by":"crossref","unstructured":"Norris AW. et al. Survival in a bad neighborhood: pancreatic islets in cystic fibrosis. J Endocrinol JOE-18-0468.R1 (2019) doi:10.1530\/JOE-18-0468.","DOI":"10.1530\/JOE-18-0468"},{"key":"10.1016\/j.prrv.2022.11.005_b0150","doi-asserted-by":"crossref","unstructured":"Guo JH. et al. Glucose-induced electrical activities and insulin secretion in pancreatic islet \u03b2-cells are modulated by CFTR. Nat Commun 5, 4420 (2014).","DOI":"10.1038\/ncomms5420"},{"issue":"1","key":"10.1016\/j.prrv.2022.11.005_b0155","article-title":"Short-term CFTR inhibition reduces islet area in C57BL\/6 mice","volume":"9","author":"Khan","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.prrv.2022.11.005_b0160","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.febslet.2007.11.057","article-title":"Inflammation and insulin resistance","volume":"582","author":"de Luca","year":"2008","journal-title":"FEBS Lett"},{"issue":"8","key":"10.1016\/j.prrv.2022.11.005_b0165","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98240","article-title":"Cystic fibrosis-related diabetes is caused by islet loss and inflammation","volume":"3","author":"Hart","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.prrv.2022.11.005_b0170","doi-asserted-by":"crossref","unstructured":"Wang C, Guan Y, Yang J. Cytokines in the progression of pancreatic \u03b2-cell dysfunction. Int J Endocrinol 2010, 515136 (2010).","DOI":"10.1155\/2010\/515136"},{"issue":"10","key":"10.1016\/j.prrv.2022.11.005_b0175","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.2337\/db13-0510","article-title":"Genetic modifiers of cystic fibrosis-related diabetes","volume":"62","author":"Blackman","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.prrv.2022.11.005_b0180","doi-asserted-by":"crossref","unstructured":"Sun Y. et al. Expression of miRNA-29 in pancreatic \u03b2 Cells promotes inflammation and diabetes via TRAF3. Cell Rep 34, 108576 (2021).","DOI":"10.1016\/j.celrep.2020.108576"},{"key":"10.1016\/j.prrv.2022.11.005_b0185","doi-asserted-by":"crossref","unstructured":"Sun X. et al. CFTR Influences beta cell function and insulin secretion through non-cell autonomous exocrine-derived factors. Endocrinology 158, 3325\u20133338 (2017).","DOI":"10.1210\/en.2017-00187"},{"key":"10.1016\/j.prrv.2022.11.005_b0190","doi-asserted-by":"crossref","unstructured":"White MG. et al. In situ analysis reveals that CFTR is expressed in only a small minority of \u03b2-cells in normal adult human pancreas. J Clin Endocrinol Metab 105, 1366\u20131374 (2019).","DOI":"10.1210\/clinem\/dgz209"},{"key":"10.1016\/j.prrv.2022.11.005_b0195","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1741-7015-12-87","article-title":"CFTR and Anoctamin 1 (ANO1) contribute to cAMP amplified exocytosis and insulin secretion in human and murine pancreatic beta-cells","volume":"12","author":"Edlund","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.prrv.2022.11.005_b0200","doi-asserted-by":"crossref","unstructured":"Di Fulvio M. et al. Heterogeneous expression of CFTR in insulin-secreting \u03b2-cells of the normal human islet. PLoS One 15, e0242749 (2020).","DOI":"10.1371\/journal.pone.0242749"},{"key":"10.1016\/j.prrv.2022.11.005_b0205","doi-asserted-by":"crossref","unstructured":"Milner AD. Blood glucose and serum insulin levels in children with cystic fibrosis. Arch Dis Childhood 44, 351\u2013355 (1969).","DOI":"10.1136\/adc.44.235.351"},{"issue":"8","key":"10.1016\/j.prrv.2022.11.005_b0210","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1164\/rccm.201512-2518OC","article-title":"Abnormal glucose tolerance in infants and young children with cystic fibrosis","volume":"194","author":"Yi","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.prrv.2022.11.005_b0215","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jcf.2020.02.009","article-title":"Glucose abnormalities detected by continuous glucose monitoring are common in young children with Cystic Fibrosis","volume":"19","author":"Prentice","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.prrv.2022.11.005_b0220","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcf.2013.11.005","article-title":"Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients","volume":"13","author":"Leclercq","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.prrv.2022.11.005_b0225","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.prrv.2022.11.005_b0230","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.prrv.2022.11.005_b0235","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcf.2018.07.010","article-title":"Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor","volume":"18","author":"Li","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2022.11.005_b0240","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.rmed.2017.08.026","article-title":"Ivacaftor for the p.Ser549Arg (S549R) gating mutation \u2013 The Israeli experience","volume":"131","author":"Dagan","year":"2017","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.prrv.2022.11.005_b0245","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jpeds.2007.05.012","article-title":"Glucose tolerance, insulin secretion, and insulin sensitivity in children and adolescents with cystic fibrosis and no prior history of diabetes","volume":"151","author":"Elder","year":"2007","journal-title":"J Pediatr"},{"key":"10.1016\/j.prrv.2022.11.005_b0250","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1183\/09031936.05.00068104","article-title":"New criteria for impaired fasting glucose and screening for diabetes in cystic fibrosis","volume":"25","author":"Mueller-Brandes","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2022.11.005_b0255","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/bmj.311.7006.655","article-title":"Glucose tolerance in patients with cystic fibrosis: five year prospective study","volume":"311","author":"Lanng","year":"1995","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.prrv.2022.11.005_b0260","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jpeds.2009.10.019","article-title":"Natural history of glucose intolerance in patients with cystic fibrosis: ten-year prospective observation program","volume":"156","author":"Sterescu","year":"2010","journal-title":"J Pediatr"},{"issue":"12","key":"10.1016\/j.prrv.2022.11.005_b0265","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.2337\/dc10-0613","article-title":"Impaired fasting glucose in cystic fibrosis","volume":"33","author":"Frohnert","year":"2010","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.prrv.2022.11.005_b0270","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/pedi.12026","article-title":"Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study","volume":"14","author":"Bellin","year":"2013","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.prrv.2022.11.005_b0275","doi-asserted-by":"crossref","unstructured":"Tsabari, R. et al. CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation. J Cyst Fibros 15, e25-27 (2016).","DOI":"10.1016\/j.jcf.2015.10.012"},{"issue":"3","key":"10.1016\/j.prrv.2022.11.005_b0280","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1164\/rccm.201806-1018OC","article-title":"Islet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy","volume":"199","author":"Kelly","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"485","key":"10.1016\/j.prrv.2022.11.005_b0285","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.prrv.2022.11.005_b0290","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcf.2017.11.016","article-title":"Effect of Lumacaftor\/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients","volume":"17","author":"Thomassen","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.prrv.2022.11.005_b0295","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jcf.2020.09.001","article-title":"Lumacaftor\/ivacaftor therapy fails to increase insulin secretion in F508del\/F508del CF patients","volume":"20","author":"Moheet","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.prrv.2022.11.005_b0300","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jcf.2020.03.002","article-title":"Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients","volume":"19","author":"Misgault","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.prrv.2022.11.005_b0305","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s40618-021-01525-4","article-title":"Lumacaftor\/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion","volume":"44","author":"Colombo","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.prrv.2022.11.005_b0310","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.852551","article-title":"Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis-an observational pilot study","volume":"10","author":"Korten","year":"2022","journal-title":"Front Pediatr"},{"issue":"2","key":"10.1016\/j.prrv.2022.11.005_b0315","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.prrv.2022.11.005_b0320","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"Bessonova","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.prrv.2022.11.005_b0325","doi-asserted-by":"crossref","unstructured":"Christian, F. et al. Sustained glycemic control with ivacaftor in cystic fibrosis-related diabetes. J Investig Med High Impact Case Rep 7, 2324709619842898 (2019).","DOI":"10.1177\/2324709619842898"},{"key":"10.1016\/j.prrv.2022.11.005_b0330","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1164\/rccm.201405-0882LE","article-title":"Resolution of cystic fibrosis-related diabetes with ivacaftor therapy","volume":"190","author":"Hayes","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2022.11.005_b0335","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jcf.2016.09.005","article-title":"Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation","volume":"16","author":"Mutyam","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2022.11.005_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107845","article-title":"Effect of CFTR modulator therapy on cystic fibrosis-related diabetes","volume":"35","author":"Gaines","year":"2021","journal-title":"J Diabetes Compl"},{"key":"10.1016\/j.prrv.2022.11.005_b0345","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2022.11.005_b0350","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054222000860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054222000860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:36:52Z","timestamp":1761507412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054222000860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":70,"alternative-id":["S1526054222000860"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2022.11.005","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystic fibrosis related diabetes (CFRD) in the era of modulators: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2022.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}